Compounds > 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cobalt

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with cobalt in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barbeau, A; Donaldson, J; Poirier, J1
Bloomquist, JR; Klorig, DC; Kou, J1

Other Studies

2 other study(ies) available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cobalt

ArticleYear
The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals.
    Biochemical and biophysical research communications, 1985, Apr-16, Volume: 128, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Cobalt; Dopamine; Drug Synergism; Free Radicals; Humans; Hydroxides; Hydroxyl Radical; Iron; Manganese; Metals; Oxidation-Reduction; Pyridines; Substantia Nigra; Superoxide Dismutase; Zinc

1985
Potentiating effect of the ATP-sensitive potassium channel blocker glibenclamide on complex I inhibitor neurotoxicity in vitro and in vivo.
    Neurotoxicology, 2006, Volume: 27, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphate; Animals; Blotting, Western; Calcium; Cobalt; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Electron Transport Complex I; Glyburide; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Neurotoxicity Syndromes; Potassium Channel Blockers; Rotenone; Tyrosine 3-Monooxygenase

2006